• About Nektar
  • Our Leadership
  • Corporate Giving
  • Locations
  • Contacts
• Pipeline
  • Pipeline Overview
  • Nektar Proprietary Products
  • Nektar Partnered Products
  • Drug Development Platforms
• Partners
  • Nektar Partners
• Investor Relations
  • Press Releases
  • Stock Information
  • Financial Events Calendar
  • Analyst Coverage
  • Annual and Financial Reports
  • Corporate Governance
  • Investor Contacts
  • FAQ
  • Investor Advisory
• Media Room
  • Lead Product Backgrounder
  • Press Releases
  • Press Kit
  • Media Contacts
• Information Center
  • Scientific & Partnering Events
  • Multimedia
  • Library
  • Email Alerts
• Careers
  • Life at Nektar
  • Career Opportunities
  • Recruitment Calendar
  • Summer Internships
  • Benefits
  • Recruiting Information
  • Nektar Employee Foundation

• Pipeline Overview
• Nektar Proprietary Products
  • NKTR-102
    (PEG-irinotecan)
  • NKTR-118
    (oral PEG-naloxol)
  • NKTR-024
    (amphotericin B inhalation powder)
• Nektar Partnered Products
• Drug Development Platforms

With the knowledge and experience gained from our past successes in drug development, comes a capacity to innovate that is clearly reflected in our proprietary products.

• NKTR-102 (PEG-irinotecan)
• NKTR-118 (oral PEG-naloxol)
• NKTR-024 (amphotericin B inhalation powder)